EAM
ADMS

EverPoint Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

EverPoint Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-360,000
Closed -$9.44M – 558
2015
Q2 		$9.44M Buy
+360,000
New +$7M 0.17% 182

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EverPoint Asset Management's ADMS Position: Q3 2015 in Review

EverPoint Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2015, closing a stake of 360,000 shares — an estimated $9.44M sold.

EverPoint Asset Management first reported a position in ADMS in Q2 2015 and held it in 1 quarter. The position peaked at $9.44M in Q2 2015. 83 funds tracked by Wall St. Rank hold ADMS as of Q3 2015.

  • EverPoint Asset Management reported no remaining Adamas Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 360,000 Adamas Pharmaceuticals shares in Q3 2015, an estimated $9.44M.
  • EverPoint Asset Management first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • EverPoint Asset Management's Adamas Pharmaceuticals position peaked at $9.44M in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2015.

Based on EverPoint Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.